ライフサイエンスコーパス: acellular

1 llularization of whole organs for generating acellular 3D scaffolds with preserved ECM protein conten

2 Surprisingly, we found that an acellular accessory structure close to the stereocilia,

3 High levels of free acellular adult hemoglobin (free HbA) are associated wit

4 A properly designed acellular and biodegradable TEVG must encourage the infi

5 expand and directly contribute to postnatal acellular and cellular cementum growth.

6 oot and periodontal apparatus, including the acellular and cellular cementum, periodontal ligament (P

7 n surgically resected lobes were perfused in acellular and normothermic condition.

8 osols as measured by the dichlorofluorescein acellular assay but not by the uric acid, ascorbic acid,

9 nicotinamide were evaluated using a panel of acellular assays and lipopolysaccharide-stimulated RAW 2

10 ed PM(2.5) samples was compared through four acellular assays, and OP predictive capability was evalu

11 Additionally, in acellular assays, peptides were cross-linked in the pres

12 ella colonization factor A (BcfA) to develop acellular B. bronchiseptica vaccines in the absence of a

13 Acellular biological scaffolds, or decellularized extrac

14 substituted at 8 weeks, in opposition to the acellular biomaterial group.

15 Injectable, acellular biomaterials hold promise to limit left ventri

16 MSCs)-seeded bone microparticles compared to acellular bone microparticles alone.

17 +/- 10.58 mm(3), p = 0.029), compared to the acellular bone microparticles.

18 16s RNA gene sequencing was performed on acellular bronchoalveolar lavage (BAL) fluid from 30 sub

19 mass spectrometry based proteome analysis of acellular bronchoalveolar lavage (BAL) fluid samples on

20 By evaluating both upper airway and acellular bronchoalveolar lavage samples from 49 subject

21 We have previously demonstrated that acellular bronchoalveolar lavage samples from half of th

22 dard for OCS); (2) whole blood (WB); and (3) acellular buffered dextran-albumin solution (analogous t

23 E35, the optic chiasm and optic tract remain acellular, but the latter contains radial processes with

24 and morphological characteristics including acellular capillaries (AC) and pericyte loss (PL), vesse

25 e effect of reduced Cx30.2 on development of acellular capillaries (ACs) and pericyte loss (PL) was s

26 6 months of diabetes, the number of retinal acellular capillaries almost doubled compared with diabe

27 (-/-), and LXRalpha/beta(-/-) mice developed acellular capillaries and EPC dysfunction similar to the

28 Retinas were evaluated for number of acellular capillaries and glial fibrillary acidic protei

29 AKT phosphorylation, and increased number of acellular capillaries and pericyte loss compared with th

30 vels, AKT phosphorylation, and the number of acellular capillaries and pericyte loss compared with th

31 TZ/WD mice, GW3965 treated mice showed fewer acellular capillaries and reduced GFAP expression.

32 r mm(2)) the diabetes-associated increase of acellular capillaries and the increase of infiltrating i

33 Eyes were enumerated for acellular capillaries and were stained for oxidative dam

34 upregulated at longer duration when retinal acellular capillaries begin to increase.

35 al digestion using trypsin was performed and acellular capillaries enumerated.

36 The number of acellular capillaries increased threefold, and nitrotyro

37 , including vascular tortuosity, obliterated acellular capillaries, and pericyte ghosts.

38 oss but no difference in pericyte density or acellular capillaries.

39 human scale and obtained biocompatible human acellular cardiac scaffolds with preserved extracellular

40 ecrease in eruption rate is due to a lack of acellular cementum and associated defective periodontal

41 sion and function of BSP in the formation of acellular cementum and periodontal attachment are well d

42 Nonsignificant changes in acellular cementum did not appear to affect periodontal

43 In Phospho1(-/-) mice, acellular cementum formation and mineralization were una

44 nd cellular cementum, further revealing that acellular cementum formation is not substantially regula

45 and SEM revealed a significant reduction in acellular cementum formation on Bsp (-/-) mouse molar an

46 ggest that BSP plays a non-redundant role in acellular cementum formation, likely involved in initiat

47 periodontal tissue breakdown, with a lack of acellular cementum leading to periodontal ligament detac

48 utant mouse molars revealed 4-fold increased acellular cementum thickness ( P = 0.002) and 5-fold inc

49 llular cementogenesis plus a transition from acellular cementum to cellular cementum.

50 Acellular cementum was thin and showed periodontal ligam

51 short molar roots with thin dentin, lack of acellular cementum, and osteoid accumulation in alveolar

52 phosphate (PP(i)) and a severe deficiency in acellular cementum.

53 Our method yields highly aligned, acellular collagen constructs with predictable microstru

54 biogeochemical cycling of both cellular and acellular community components.

55 ons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, i

56 The acellular component of this stroma has been implicated i

57 plaques and uncovers their volume, geometry, acellular component, surface, and spatial position withi

58 ructs was significantly greater than that of acellular constructs after 1 and 3 months.

59 Cellular and acellular constructs were implanted subcutaneously in th

60 rms of plaque volume, geometry, and ratio of acellular core to plaque volume.

61 andibular bone augmentation, compared to its acellular counterpart.

62 Of these 37, 30 (81%) had implantation of acellular dermal allograft (ADA) and 7 (19%) implantatio

63 Acellular dermal matrices have many current and potentia

64 The long-term outcomes of acellular dermal matrix (ADM) for the treatment of isola

65 controlled clinical trial was to compare two acellular dermal matrix (ADM) materials produced by diff

66 can be treated by various methods, including acellular dermal matrix (ADM) or coronally advanced flap

67 of bilateral recession defects treated with acellular dermal matrix (ADM) with and without recombina

68 hickness (MT) 1 year after treatment with an acellular dermal matrix (ADM).

69 issue graft [CTG], collagen matrix [CM], and acellular dermal matrix [ADM]) resulted in a significant

70 showed that all investigated techniques (the acellular dermal matrix [ADM], collagen matrix [CM], con

71 Acellular dermal matrix graft (ADMG) or enamel matrix de

72 amounts of keratinized tissue (KT) with the acellular dermal matrix graft (ADMG).

73 ence of a difference in GR reduction between acellular dermal matrix grafts (ADMG) + CAF and SCTG + C

74 procedures and coronally advanced flap plus acellular dermal matrix grafts, enamel matrix derivative

75 Three of the 4 commonly used acellular dermal matrix materials are resistant to in vi

76 human allograft putty, and then covered with acellular dermal matrix membrane.

77 of the gingival margin over time, while EMD, acellular dermal matrix, collagen matrix, and flap alone

78 A non-cross-linked porcine acellular dermal mesh was sutured to the pelvic floor re

79 ted maxillofacial implants and other printed acellular devices have been used in patients.

80 plicate implants were used in this study: 1) acellular dTBs; 2) recellularized dTBs seeded with porci

81 al systems composed of distinct cellular and acellular elements that collectively dictate glioblastom

82 which still undergoes apical constriction in acellular embryos as in wildtype.

83 tem without polarized cell intercalation, in acellular embryos.

84 hat fail to form cells before gastrulation ('acellular' embryos), such that the global redistribution

85 on of the seminiferous tubules, which become acellular, empty spaces among the extant Leydig cells.

86 the myocardium and outperforms most existing acellular epicardial patches in reversing left ventricul

87 Acellular epicardial patches that treat myocardial infar

88 Stabilized, acellular, equine pericardial collagen matrix (sPCM) wou

89 e various concentrations and combinations of acellular extracellular matrix (ECM) components that may

90 Our study aims at producing acellular extracellular matrix scaffolds from the human

91 Complex acellular facial scaffolds were obtained, preserving sim

92 dhesion interface, allowing formation of the acellular fissure that defines the somite boundary.

93 lavage fluid was separated into cellular and acellular fractions by centrifugation.

94 G2 RSs injected with acellular GelMA alone, and G3 empty RSs were used as con

95 In contrast, acellular GelMA and empty RS constructs supported the fo

96 ived pulp-like tissue was observed in the G2 acellular GelMA and G3 empty RS groups.

97 cnemius muscle recovery at 5 months than the acellular group, but the NCSC-SC group didn't.

98 eks in the cell-seeded group compared to the acellular group, thereby demonstrating a higher rate of

99 3.00 +/- 0.61, P = 0.163) than the low-flow acellular group.

100 r in Anopheles gambiae, we show here that an acellular gut barrier, resulting from the tyrosine cross

101 Alternatively, when acellular hemoglobin is diluted into blood plasma after

102 iderably slower than previously estimated in acellular hemoglobin solutions, indicating the presence

103 We present the first experience using an acellular hemoglobin-based oxygen carrier (HBOC) Hemopur

104 ts using perfluorocarbon (PFC) emulsions and acellular hemoglobin-based oxygen carriers (HBOCs).

105 Gross inspection revealed that acellular implants had significantly decreased in size b

106 rvation of an intact liver capsule, a porous acellular lattice structure with intact vessels and stri

107 liver progenitor cells self-assembled inside acellular liver extracellular matrix scaffolds to form t

108 Moreover, acellular liver scaffolds seeded with hepatocytes produc

109 r the rapid and accurate production of human acellular liver tissue cubes (ALTCs) using normal liver

110 Acellular lung matrices were prepared from whole rat or

111 Here, we tested whether acellular mammary extracellular matrix (mECM) preparatio

112 Enamel is an acellular material formed by the intricate process of am

113 Acellular materials of xenogenic origin are used worldwi

114 ed environment of supporting cells (SCs) and acellular matrices.

115 of the decellularised scaffolds revealed an acellular matrix with histological preservation of struc

116 plastic support, MatrigelTM and human liver acellular matrix.

117 This layer was acellular, measured 10.15 +/- 3.6 microns composed of 5

118 Otogelin-like is localized to the acellular membranes of the cochlea and the vestibular sy

119 A complementary in vitro acellular mineralization study revealed that the hydroge

120 Enamel, the outermost layer of teeth, is an acellular mineralized tissue that cannot regenerate; the

121 to infiltrate and grow in CSF, a remarkably acellular, mitogen-poor metastasis microenvironment.

122 en implanted into rat osteochondral defects, acellular nanofiber scaffolds supported enhanced chondro

123 Because of their acellular nature, iPSC-EVs represent a safer alternative

124 le-perfusion system and a haemoglobin-based, acellular, non-coagulative, echogenic, and cytoprotectiv

125 The recent development of acellular OP measurement techniques has led to a surge i

126 Implantation of acellular or endothelialized fibrin grafts with an exter

127 y divided and perfused using either low-flow acellular or high-flow cellular EVLP systems (n = 8, eac

128 No inflammation was observed in either acellular or MSC-seeded scaffolds.

129 nic components, have been mostly replaced by acellular or subunit vaccines composed of well-defined,

130 aluate the effects of hypothermic MP with an acellular perfusate in human upper extremities and compa

131 alyzed comparative responses to cellular and acellular perfusates to identify these benefits.

132 Acellular perfusion was limited to 6 hours on the OCS sy

133 Acellular pertussis (aP) and whole-cell (wP) pertussis v

134 e efficacy and duration of protection of the acellular pertussis (aP) vaccine is lower than that of t

135 A maternal monovalent acellular pertussis (aP) vaccine, in development, could

136 nia in an cohort vaccinated exclusively with acellular pertussis (aP) vaccine.

137 tely understood, we hypothesize that current acellular pertussis (aP) vaccines fail to prevent coloni

138 Protection induced by acellular pertussis (aP) vaccines is partial and short-l

139 In England, acellular pertussis (aP) vaccines replaced whole-cell pe

140 ing immunity induced after immunization with acellular pertussis (aP) vaccines.

141 Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2,

142 Infants received either acellular pertussis (aP)- or wP-containing vaccine at 2,

143 Pertussis antibody titers are higher in acellular pertussis (aP)- than wP-vaccinated infants of

144 Maternal vaccination with an acellular pertussis (aP)-containing vaccine is a recomme

145 ay in vaccines containing diphtheria-tetanus-acellular pertussis (DTaP) is associated with reduced ri

146 ceive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age

147 ion for the diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine.

148 omen immunized with tetanus, diphtheria, and acellular pertussis (Tdap) after the 20th week of their

149 hird-trimester (>/=GW 26) tetanus-diphtheria-acellular pertussis (Tdap) immunization in pregnant wome

150 on between prenatal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination and risk of atten

151 mended to receive a tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at 27-36 weeks gestat

152 ommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at the start of the t

153 The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine booster between 2 con

154 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine could prevent infant

155 ers vaccinated with tetanus, diphtheria, and acellular pertussis (Tdap) vaccine during pregnancy in T

156 recommend tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine for postpartum women

157 CIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for pregnant women du

158 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was recommended for a

159 gh-income countries using tetanus-diphtheria-acellular pertussis (Tdap) vaccines in their maternal an

160 o mothers vaccinated with tetanus-diphtheria-acellular pertussis (Tdap)-vaccine during pregnancy in T

161 mbination diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovi

162 heduled administration of tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respecti

163 For acellular pertussis antigens, 2-fold higher maternal ant

164 oduction and persistence of antibodies after acellular pertussis booster vaccination during adolescen

165 veness of US-licensed vaccines containing an acellular pertussis component.

166 and after they received a priming series of acellular pertussis containing vaccines.

167 nfants aged <2 months whose mothers received acellular pertussis during the third trimester and child

168 commended universal tetanus, diphtheria, and acellular pertussis immunisation during pregnancy.

169 priming dose of wP vaccine into the current acellular pertussis vaccination schedule.

170 superior protection contrasted with a solely acellular pertussis vaccine (aP) series.

171 te vaccination program of the currently used acellular pertussis vaccine (aPV).

172 group despite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage, indicating

173 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered durin

174 n with tetanus, reduced-dose diphtheria, and acellular pertussis vaccine (Tdap) could be an effective

175 ine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertus

176 hed data on the safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in persons aged >/=65

177 n healthcare personnel (HCP) vaccinated with acellular pertussis vaccine (Tdap).

178 e dose of diphtheria and tetanus toxoids and acellular pertussis vaccine 10 years ago, during adolesc

179 Baboons receiving acellular pertussis vaccine and infants born to mothers

180 Baboons were vaccinated with acellular pertussis vaccine at 2 days of age or at 2 and

181 ate the genetics of antibody responses to an acellular pertussis vaccine by a genome-wide association

182 eived at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine by the end of 15 months of a

183 of earlier or more numerous booster doses of acellular pertussis vaccine either as part of routine im

184 theria booster with tetanus, diphtheria, and acellular pertussis vaccine for adolescents and adults)

185 with diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine has been associated with som

186 In Denmark, acellular pertussis vaccine has been included in the com

187 izures, but whether this risk applies to the acellular pertussis vaccine is not known.

188 The population-level safety benefits of the acellular pertussis vaccine may have been underestimated

189 It appears that a wholly acellular pertussis vaccine series is significantly less

190 accination, adult female baboons primed with acellular pertussis vaccine were boosted in the third tr

191 1994 and March 1996 (before introduction of acellular pertussis vaccine) and between April 1998 and

192 l 1998 and March 2000 (after introduction of acellular pertussis vaccine) in Ontario, Canada.

193 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine).

194 There is accumulating literature on waning acellular pertussis vaccine-induced immunity, confirming

195 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine.

196 eceipt of diphtheria and tetanus toxoids and acellular pertussis vaccine.

197 tand the effect of vaccination in the era of acellular pertussis vaccines (DTaP and Tdap), we assesse

198 s that received different diphtheria-tetanus-acellular pertussis vaccines (DTaP) during childhood and

199 ssis has been linked to switch to the use of acellular pertussis vaccines and the evolution of Bordet

200 optimal and short-lived immunity elicited by acellular pertussis vaccines and to their inability to p

201 easing evidence that the currently available acellular pertussis vaccines are not providing optimal c

202 y inactivated influenza, tetanus toxoid, and acellular pertussis vaccines are recommended during preg

203 ciated adverse events led the development of acellular pertussis vaccines containing 1 or more purifi

204 y in mice, it is not included in any current acellular pertussis vaccines due to protein stability is

205 Current acellular pertussis vaccines may not protect against tra

206 d whole-cell pertussis vaccines, and OPV and acellular pertussis vaccines were similar.

207 her vaccines (most commonly pneumococcal and acellular pertussis vaccines), whereas standalone IPV va

208 te recommendations that older adults receive acellular pertussis vaccines, data on direct effectivene

209 at 10 years after high childhood coverage of acellular pertussis vaccines.

210 rogram and the transition from whole-cell to acellular pertussis vaccines.

211 and diphtheria; and tetanus, diphtheria, and acellular pertussis vaccines.

212 gate, and tetanus and diphtheria toxoids and acellular pertussis vaccines.

213 ns for the defects in immunity stimulated by acellular pertussis vaccines.

214 tanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women d

215 scent and adult tetanus, reduced diphtheria, acellular pertussis) vaccine.

216 ty infants of Tdap (tetanus, diphtheria, and acellular pertussis)-vaccinated pregnant women and 37 in

217 ent in reduced responses to booster doses of acellular pertussis, inactivated polio, and diphtheria v

218 eumococcal and combined diphtheria, tetanus, acellular pertussis, inactivated polio, hepatitis B, Hae

219 oxyfen or vaccines (tetanus, diphtheria, and acellular pertussis, measles and rubella, or measles, mu

220 ations of diphtheria and tetanus toxoids and acellular pertussis, meningococcal conjugate and pneumoc

221 ations of diphtheria and tetanus toxoids and acellular pertussis, pneumococcal conjugate, and human p

222 program using diphtheria-tetanus-5-component acellular pertussis-inactivated polio vaccine (dT5aP-IPV

223 mary doses of the diphtheria-tetanus toxoids-acellular pertussis-inactivated poliomyelitis-Haemophilu

224 d in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus-Haemophilus i

225 ation diphtheria vaccine (diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus i

226 t limb group received the diphtheria-tetanus-acellular pertussis-inactived polio-Haemophilus influenz

227 2010, corresponding directly to the aging of acellular pertussis-vaccinated cohorts.

228 xoid, reduced diphtheria toxoid, and reduced acellular pertussis; and human papillomavirus vaccines)

229 ng a tetanus/low-dose diphtheria/5-component acellular-pertussis/inactivated-polio (TdaP5/IPV) vaccin

230 ammation, the long-term safety of living and acellular pig tissue implants in recipients warrants fur

231 om the cellular (circulating leukocytes) and acellular (plasma cell-free DNA) compartments of periphe

232 engineered transcatheter valve scaffolds (1) acellular porcine pericardium and (2) mesenchymal stem c

233 MSC-seeded and acellular porcine pericardium expressed decreased inflam

234 cardium and (2) mesenchymal stem cell-seeded acellular porcine pericardium were compared to native po

235 evidence for the existence of a distinctive acellular pre-Descemet's stromal layer in the human corn

236 well-studied chick, the mouse cornea had no acellular primary stroma.

237 and 11-18 years coincided with the aging of acellular-primed cohorts.

238 rating host cells make contact only with the acellular protective coat of the parasite, called lamina

239 can be used as a novel tool for cellular and acellular regenerative medicine approaches for osteoarth

240 ation grade 2R or higher cellular rejection, acellular rejection, or allograft dysfunction of uncerta

241 n protocol enabled us to obtain a completely acellular renal scaffold while maintaining the extracell

242 pod flavors generated significant amounts of acellular ROS and induced significant mitochondrial supe

243 the species responsible for the majority of acellular ROS in this printer.

244 ition, the benefit of utilizing a biomimetic acellular scaffold as an advanced 3D culture system to m

245 One approach combines cells with acellular scaffolds derived from animal tissue.

246 Acellular scaffolds obtained via decellularization are a

247 n all facial grafts within 12 days revealing acellular scaffolds with full preservation of innate mor

248 uctural and biochemical properties of native acellular scaffolds with subsequent recellularization te

249 man kidneys by detergent perfusion, yielding acellular scaffolds with vascular, cortical and medullar

250 Decellularized (acellular) scaffolds, composed of natural extracellular

251 dge with scar tissue); 1 eye showed a dense, acellular scar overlying a portion of the DMEK graft tha

252 This is a plasmodial, vegetative stage of acellular slime mould.

253 utions, artificial hemoglobin solutions, and acellular solutions have all been utilized in NMP.

254 thermic ex situ perfusion with an oxygenated acellular Steen solution may extend the allowable extrac

255 There exists a novel, well-defined, acellular, strong layer in the pre-Descemet's cornea.

256 ereocilia in the tectorial membrane (TM), an acellular structure overlying the sensory epithelium.

257 ounds, especially those containing permanent acellular structures, such as scar tissue.

258 This is an acellular system that reproduces the assembly of part of

259 ibited a high radical scavenging activity in acellular systems.

260 Recently our group demonstrated that acellular tissue engineered vessels (A-TEVs) comprised o

261 nd promote endothelialization and patency of acellular tissue-engineered vessels (A-TEVs) into the ar

262 d from each fraction were quantified with an acellular Trolox-based liquid chromatography-electrospra

263 llularization of porcine urethras to produce acellular urethra bioscaffolds for future tissue enginee

264 sed to evaluate the recellularization of the acellular urethra bioscaffolds.

265 ghlight discrepancies between whole-cell and acellular vaccination that could contribute to the incre

266 infection since the transition to the use of acellular vaccination.

267 Importantly, we demonstrate that acellular vaccine antigen-encoding genes are evolving at

268 pertussis without the pertactin protein, an acellular vaccine immunogen, has been reported in the Un

269 It has been suggested that acellular vaccine may be less effective than previously

270 ion was able to prevent transmission, but an acellular vaccine that effectively controls disease fail

271 ents taking place before introduction of the acellular vaccine versus after introduction by calculati

272 ts introduction, despite changing to another acellular vaccine with different antigen composition.

273 aring event rates before the introduction of acellular vaccine with those after introduction.

274 s per month were avoided by switching to the acellular vaccine, which is a 38-fold higher impact than

275 vaccines; (7) memory B cells persist in both acellular vaccine- and whole cell vaccine-primed childre

276 arrying prn2 and ptxP3 under the pressure of acellular vaccine-induced immunity.

277 ole cell vaccine-primed children; and (8) in acellular vaccine-primed children, T-cell responses rema

278 rs; range, 46-81 years) within 5 years after acellular vaccine.

279 relative incidence after introduction of the acellular vaccine.

280 years, range 46-81) within five years after acellular vaccine.

281 Current acellular vaccines against Bordetella pertussis are effe

282 n this article we discuss the following: (1) acellular vaccines are immunogenic, but responses vary b

283 s is resurging in a number of areas in which acellular vaccines are the primary vaccine administered

284 vaccination, inferior long-term efficacy of acellular vaccines compared with whole-cell vaccines, ci

285 minantly T-helper 1 (Th1) responses, whereas acellular vaccines generate mixed Th1/Th2 responses; (5)

286 Though acellular vaccines have been in use for 20 years, new da

287 suggest a central role of the transition to acellular vaccines in the US disease resurgence.

288 The efficacy of acellular vaccines is inferior to that of WCVs, however,

289 However, waning of immunity from acellular vaccines may be driving the recent resurgence

290 In countries using acellular vaccines, waning immunity is at least part of

291 ounced since the introduction of the current acellular vaccines.

292 immunogenicity, and/or efficacy of different acellular vaccines.

293 ut suppression has been seen less often with acellular vaccines; (7) memory B cells persist in both a

294 Acellular valve scaffolds expressed CD163, CD31, alpha s

295 ribute directly to the endothelialization of acellular vascular grafts under the right chemical and b

296 e developed and tested a bioengineered human acellular vessel as a potential solution to these limita

297 A novel bioengineered human acellular vessel was implanted into the arms of patients

298 Bioengineered human acellular vessels seem to provide safe and functional ha

299 Human acellular vessels were implanted into 60 patients.

300 ore penetrating keratoplasty demonstrated an acellular zone with a hyperintense signal consistent wit